Brokerage : Daishin Securities
Analyst : Kahye Hong
Investment Rating : BUY (Maintained)
Target Price : KRW 2,000,000 (Maintained)
Core Momentum : By acquiring Swiss peptide specialist PolyPeptide Group for approximately KRW 2.7 trillion, the company achieves rapid entry into the high-growth GLP-1 peptide market and secures a multi-regional global manufacturing network.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY rating maintained; 6-month Target Price maintained at KRW 2,000,000 (vs. closing share price of KRW 1,345,000).
- Valuation Methodology & Treatment: The acquisition of PolyPeptide Group is evaluated as a structurally positive strategic milestone; however, post-deal integration synergies are not yet reflected in the target price calculation pending transaction completion.
- Market Indicators (As of 2026.07.20):
- KOSPI: 6,516.27pt
- Market Capitalization: KRW 62.261 trillion
- 52-Week High / Low: KRW 1,965,000 / KRW 996,000
- Foreign Ownership: 12.81%
- Major Shareholders: Samsung C&T and 5 others (74.30%), National Pension Service (6.68%)
🚀 2. [Market Opportunities & Business Outlook]
- Overview of PolyPeptide Group Acquisition:
- Disclosed transaction on July 20 to acquire Switzerland-based peptide CDMO PolyPeptide Group (SIX: PPGN).
- Deal Size: Approximately KRW 2.7 trillion (tender offer scheduled to run for ~2 months starting September; high closing visibility backed by major shareholder tendering commitment).
- Timeline: Targeting transaction closing by year-end.
- Funding: Significant portion covered by internal cash reserves and operating cash flows (potential for additional debt financing remains given ongoing CAPEX for Plant 6 and Campus 3).
- Target Company (PolyPeptide Group) Operational Profile & Guidance:
- Specialist peptide CDMO with ~70 years of track record, operating 6 cGMP manufacturing facilities across the US, Europe, and India.
- Manufacturing experience with over 1,000 peptide therapeutics and holding contracts for ~one-third of global Phase 3 peptide pipelines.
- 2025 Revenue reached EUR 389 million (metabolic disease sales share expanded rapidly from 22% in 2021 to 57% in 2025).
- 2026 Guidance: Revenue growth of 20–25% YoY with EBITDA margin in the mid-to-high teens.
- Strategic Rationale & Long-term Synergies:
- Rapid entry into the surging GLP-1 obesity/diabetes peptide market via M&A, substantially shortening time-to-market compared to greenfield capacity expansion.
- Immediate top-line contributions post-closing by inheriting established facilities and global client bases.
- Bolstered supply chain resilience across US, European, and Indian sites, creating upside from cross-selling synergies and operational efficiencies.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics not merely as a single-modality mammalian antibody manufacturer, but as an expanding multi-modality global CDMO capturing surging GLP-1 obesity and diabetes demand while instantly acquiring a multi-regional production footprint across the US, Europe, and India through the PolyPeptide Group buyout. The perspective places premium value on the accelerated time-to-market and strategic supply chain diversification achieved via acquisition compared to time-consuming organic greenfield expansion.
To verify whether this investment thesis unfolds as anticipated, key monitoring milestones include tracking the progress of the tender offer launching in September through its year-end closing, evaluating the final financing structure (ratio of internal cash flow vs. additional debt) amid ongoing Campus 3 and Plant 6 CAPEX, and observing actual cross-selling execution between antibody clients and peptide pipelines starting in 2027. These developments can be verified through tender offer outcome disclosures, equity acquisition filings on DART, and subsequent periodic earnings reports and IR releases.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
